Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes but a good reminder of the many potentials and values for Brilacidin.
It is a long list of Brilacidin potentials here:https://scholar.google.com/scholar?as_sdt=40007&q=brilacidin&hl=en
Ipix sleeps until BeaMed receives USA FDA approval for their new system.
The independent scholars and scientists who find all Brilacidin can do do not sleep.
Thank you, over the years you've always been the source of great info that folks like our, self proclaimed resident Ipix scientist wants to dismiss. Therefore as far as I know it's been suppressed.
Besides, we all know the drug and the company is Dead...
frenchfraud’s salad shooting. priceless.
Your days of scamming investors using this ticker are over.
This shit ain’t sleepin. It’s dead. Never to be resurrected.
Nope. I said your days of scamming investors using this ticker are over.
“ You say I want to persuade investors to buy action of a stock that can not today be bought??”
On the plus side the shares can still be sold.
LOL. "...a stock that can not today be bought." That is all one needs to know about this mess Ehrlich created. A garbage stock.
You say I want to persuade investors to buy action of a stock that can not today be bought??
This is funny.
Latest addition to the old “otc portfolio” I suspect.
This shit ain’t sleepin. It’s dead. Never to be resurrected. Your days of scamming investors using this ticker are over.
"I expect a Ipix wake up and filing and re-trading before November."
You do?
I don't think so. I think you would do just as well by following tb to IPIX 2.0 (wherever that is).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174682518
Q2 2024 is over and the middle of 2024 is here.
So those of you Ipix investors who feel smitten and broke, "follow" me to Ipix 2.0.
Or email me at tbnlp@juno.com
From the last press release on the IPIX website...issued on August 28, 2023.
BeaMed is on track to submit, in Q2 2024, the System for potential FDA approval via the 510(k) regulatory pathway. BeaMed’s other shareholders are the controlling shareholders of neoLaser, now the industry leader in their class of lasers in some European and Asian markets.
“The market need for new laser-based surgical technologies is significant. We fully expect BeaMed to capitalize on this opportunity as it positions itself for FDA submission by the middle of 2024,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.
His involvement with the shell he left behind certainly appears to be dead.
Perhaps another relevant question would be, Is Leo still living in the US of A?
Not sure what the relevance of allegations of fraud against a scientist associated with Cassava Sciences is to IPIX:
https://www.nytimes.com/2024/06/28/health/wang-cassava-alzheimers-fraud.html#:~:text=Dr.%20Wang%20is%20now%20accused%20of%20falsifying%20data,with%20multiple%20counts%20of%20fraud%20and%20false%20statements.
Unless you are alleging fraud against IPIX?
Certainly that's the direction that esteemed and renowned biotech analyst Adam Feuerstein, beloved amongst biotech mavens such as yourself, was pointing towards:
https://www.thestreet.com/investing/stocks/biotech-stock-mailbag-sage-therapeutics-cellceutix-alzheimer-s-risk-14058387
I'm sure the first of many.
I don't, but there's been no mention of his passing in places where you might expect to find it.
https://www.echovita.com/us/obituaries/fl/boca-raton?first_name=ehrlich
https://www.legacy.com/obituaries/search?firstName=leo%20&lastName=ehrlich
https://www.brsonline.org/ (https://www.sec.gov/Archives/edgar/data/1288099/000147793215000002/xslF345X03/form4.xml)
Do we know if Leo still alive or not?
A drug cult. Perfect.
You said your good byes in your last post....no need for more......good luck to you.....
Says one hungry jackal to another
No I held 17,000 to see what would happen. Now worth $20.40! I've seen enough. Adios
Great idea! Please wait quietly.
“ We shall see if the Cult of Ehrlich will ever abandon their leader ”
What can not be replaced is the science of Brilacidin. This is the cult I join and invest in.
The "cult of Ehrlich"? Pfft. Only a man.
What can not be replaced is the science of Brilacidin. This is the cult I join and invest in.
https://scholar.google.com/scholar?as_sdt=40007&q=brilacidin&hl=en
We shall see if the Cult of Ehrlich will ever abandon their leader who has left them in the dust....
The idiot is the one that frequents this forum with zero investment.....thats a born loser!!!!!
A final good bye idiots to Frenchbroad, PJ007, William ssc, and MackG!
You've been run over by a Mack Truck and apparently don't even realize it.
A suggestion: Forget about trying to play the biotech game.
Pick a few broad market ETF's and maybe a tech and medical ETF.
I hope you weren't counting on this POS for your retirement.
AMF
That doesn’t make any sense, FYI.
A BeaMed/IPIX scenario I read that makes sense:
A Payor Analysis began in May of 2022 regarding the use of Brilacidin in treating oral mucositis.
On June 15,2022 Leo announced the investment in Squalus/BeaMed.
On July 22 or so Leo announced the results of the Payor Analysis in a PR and the results were very good. We haven’t heard a word since then about OM. Why?
It is unlikely that this investment/reverse merger deal with BeaMed wasn’t just about the $4,000,000 and IPIX 35% cut, but the value of OM going forward and how much that could be worth to the merged company.
Leo proved the value of Brilacidin for OM to BeaMed, and a deal was signed. IPIX will go it alone with OM using BeaMed money or the SP will be high enough after the merger or the 510 FDA approval (which ever comes 1st) to invoke the Aspire deal or they do another financial deal. Considering the war in Israel, progress may have been slower than had been anticipated.
You have been posting these type of reports for some time and yet there is no apparent interest in this shell company or its one last drug to where there is a licensing agreement, partnership or buyout. Perhaps some viable company is waiting for the bankruptcy filing so it can pick it up cheap, just like End of the Line Ehrlich once did. Or maybe B is just like Ehrlich and his shell - worthless.
And I have supported the company for many many years with share purchases!!! Leo should be put in jail for all his disregard for not following his Fiduciary Duties as CEO of the company. Kips Bay should have ousted him by now!
Doesn’t mean a thing since IPIX’s CEO Leo who was a CPA by college degree has forgotten how to file an Annual or Quarterly report!!!
New report on Brilacidin anti-fungus capacity and potential. The Brilacidin work continues in Brazil and the world. The contributor list is impressive.
https://journals.asm.org/doi/10.1128/mbio.01031-24
"The global incidence of cryptococcal meningitis is estimated at more than 400,000 new cases annually, with 181,100 annual deaths (13, 14). This number corresponds to approximately 19% of AIDS-related deaths globally (14, 15). Despite the significant impact of these infections, treatment options for cryptococcosis remain limited (16, 17). In vivo experiments show BRI significantly reduces C. neoformans survival inside macrophages and partially clears C. neoformans lung infection in an immunocompetent murine model of invasive pulmonary cryptococcosis. We also observed that BRI interacts with caspofungin (CAS) and amphotericin (AmB), potentiating their mechanism of action against C. neoformans. BRI + CAS affects endocytic movement, calcineurin, and mitogen-activated protein kinases. Our results indicate that BRI is a novel antifungal drug against cryptococcosis."
French Fried....just like this sad "company."
What an odd concept!
IPIX will not progress until the laser system is approved but brilacidin is being mentioned in many many patents.
Why doesn't brilacidin wake the sleeping beauty?
5,000,000 shares would get you $6,000 at the most if you could sell it. And that's a big IF.
Ipix sleeps until USA FDA approves the new BeaMed system.
I sleep.
Those who want Brilacidin in their patents do not sleep. 11 publish this year.
https://worldwide.espacenet.com/patent/search?q=brilacidin
I see three of IPIX' most prolific advocates have gone to ground.
I think we all kniow what that means.
"Shit is happening"
Aha! A point of agreement!!!
"it ain't about the money anymore"
That's wise, 'cause the money's gone.
Last week of Q2 and not a word from the laser team! I guess there’s no point in sharing info with shareholders anymore huh leo! Not cool
Well a new antifungal patent was recently applied for. So, yes, there is still some activity.
IPIX is dead.
Leo’s last words….
“On August 29, 2023, the trial for this case commenced, and on January 18, 2024, the Court ruled in favor of Cummings, finding that Cummings is entitled to recover liquidated damages in the amount of $810,251.36, minus the Company’s $77,600 security deposit, plus eighteen percent per annum interest owing since January 17, 2020.”
"I noticed that you and your side kick had nothing to say about the paper written by a very intelligent individual regarding the prospects of Brilicidin being used to destroy Fungal infections."
Maybe you were referring to someone else but I definitely had something to say about it:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599867
Seems like William F. DeGrado has some company in terms of needing to brush up on their reading skills.
"Acknowledgements: We thank William F. DeGrado, University of California San Francisco, for his contributions to the development of the field of nonpeptide defensin mimetics, his interest in the initiation of these studies and his critique of the manuscript."
If he read it thoroughly enough to "critique" it he surely wouldn't have left this in, would he?
"Brilacidin is in human Phase 2 trials."
Or would he?
No more rumors since Leo and his associates stopped posting to this board.
Followers
|
976
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
403306
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |